Canada approves generic version of Wegovy for weight loss
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Digital Subscription
One year of digital access for only $205*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*First annual payment billed as $205.00 + GST for one year. This annual subscription will automatically renew at $233.00 + GST every 52 weeks (10% off the regular annual price of $259.35). Offer available to new and qualified returning subscribers only. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Your next Brandon Sun subscription payment will increase by $1.00 and you will be charged $17.95 plus GST for four weeks. After four weeks, your payment will increase to $24.95 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
OTTAWA – Health Canada has approved a generic version of Wegovy, a semaglutide drug that’s prescribed to help people lose weight.
The weekly injection is known as Sevmia from the Canadian company Apotex and is pharmaceutically equivalent to weight-loss medication Wegovy from Denmark’s Novo Nordisk.
Health Canada says Sevmia can be prescribed to people 12 years of age and over, as a supplement to a reduced-calorie diet and increased physical activity for weight management.
It’s the third generic semaglutide medication approved by the department, though the first two were authorized for the treatment of Type 2 diabetes in adults.
Generic versions of Novo Nordisk’s Ozempic by India-based Dr. Reddy’s Laboratories and Apotex were approved earlier this year. At the time, Apotex said its generic would be approximately one-third the price of Ozempic.
Health Canada says it’s reviewing six other submissions for generic semaglutide from different companies and expects to make more decisions in the coming weeks and months.
According to the pricing structure of the pan-Canadian Pharmaceutical Alliance, when two generic medications enter the market, they are at least 50 per cent cheaper than the brand name — but companies can price them lower.
Experts have previously estimated the cost of Wegovy to be around $400 a month, though prices can vary by dose and location.
“The availability of generic drugs is expected to have a positive impact in Canada, including potential cost savings for patients and the health-care system,” the federal agency said in a news release Monday.
This report by The Canadian Press was first published June 29, 2026.
Note to readers:This is a corrected story. A previous version misspelled Sevmia based on a press release.
